We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+15.75%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.54B
AUM Growth
+$40.4M
Cap. Flow
-$337M
Cap. Flow %
-21.88%
Top 10 Hldgs %
46.87%
Holding
259
New
90
Increased
52
Reduced
41
Closed
65

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$25.6M
2
TMP icon
Tompkins Financial
TMP
+$13.1M
3
AGEN
Agenus
AGEN
+$6.13M
4
MNKD icon
MannKind Corp
MNKD
+$5.33M
5
MDVN
MEDIVATION, INC.
MDVN
+$3.71M

Top Sells

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$28.4M
2
ABBV icon
AbbVie
ABBV
+$14.7M
3
ZTS icon
Zoetis
ZTS
+$14.2M
4
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$11.5M
5
ARWR icon
Arrowhead Research
ARWR
+$8.75M

Sector Composition

Rank Sector Weight
1 Healthcare 10.49%
2 Financials 0.07%
3 Technology 0.07%
4 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GSK icon
51
PUT
GSK
GSK
$108B
$5.92M 0.38%
+944
New +$60.8K
GEVA
52
CALL
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$5.83M 0.38%
+920
New +$45.3K
REGN icon
53
PUT
Regeneron Pharmaceuticals
REGN
$72.9B
$5.69M 0.37%
182
-385
-68% -$101K
MNKD icon
54
MannKind Corp
MNKD
$1.21B
$5.32M 0.35%
186,804
+161,203
+630% +$5.33M
BB icon
55
PUT
BlackBerry
BB
$4.74B
$5M 0.33%
+6,296
New +$61.1K
AGEN
56
Agenus
AGEN
$275M
$4.88M 0.32%
+89,859
New +$6.13M
PBF icon
57
CALL
PBF Energy
PBF
$7.22B
$4.48M 0.29%
1,995
+1,684
+541% +$38.1K
CLDX icon
58
PUT
Celldex Therapeutics
CLDX
$2.79B
$4.03M 0.26%
+76
New +$26.1K
RPRX
59
DELISTED
Repros Therapeutics Inc.
RPRX
$3.96M 0.26%
147,783
+85,693
+138% +$1.84M
ACHV icon
60
Achieve Life Sciences
ACHV
$634M
$3.81M 0.25%
187
+7
+4% +$145K
IONS icon
61
PUT
Ionis Pharmaceuticals
IONS
$9.14B
$3.76M 0.24%
+1,002
New +$29.9K
OREX
62
CALL
DELISTED
Orexigen Therapeutics, Inc.
OREX
$3.74M 0.24%
609
-151
-20% -$10.2K
TEVA icon
63
PUT
Teva Pharmaceuticals
TEVA
$36.9B
$3.59M 0.23%
950
-945
-50% -$36.9K
NWBO
64
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$3.28M 0.21%
978,359
+107,816
+12% +$375K
FOCL
65
EDAP TMS S.A.
FOCL
$227M
$3.19M 0.21%
1,259,500
+62,414
+5% +$162K
BMRN icon
66
CALL
BioMarin Pharmaceuticals
BMRN
$12B
$3.01M 0.2%
+417
New +$27.7K
ARIA
67
PUT
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$3M 0.19%
1,629
+1,151
+241% +$22.3K
NVAX icon
68
Novavax
NVAX
$1.21B
$2.77M 0.18%
+43,750
New +$2.46M
ITMN
69
PUT
DELISTED
INTERMUNE INC
ITMN
$2.6M 0.17%
1,689
– –
TEVA icon
70
CALL
Teva Pharmaceuticals
TEVA
$36.9B
$2.52M 0.16%
667
-446
-40% -$17.4K
ONXX
71
CALL
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
$2.48M 0.16%
199
-2,271
-92% -$288K
EXEL icon
72
CALL
Exelixis
EXEL
$14.2B
$2.42M 0.16%
4,167
+3,689
+772% +$19.1K
INVA icon
73
CALL
Innoviva
INVA
$1.61B
$2.38M 0.15%
722
-457
-39% -$14.2K
RPRX
74
CALL
DELISTED
Repros Therapeutics Inc.
RPRX
$2.32M 0.15%
865
+665
+333% +$14.3K
KERX
75
PUT
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$2.3M 0.15%
2,281
-6,929
-75% -$61.7K
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2013 Portfolio in Review

As of Q3 2013, Sabby Management held 259 positions worth $1.54B, up 2.7% from $1.5B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sabby Management withdrew a net $337M in Q3 2013, closing 65 positions and reducing 41 holdings. Its most notable exit was AbbVie, an estimated $14.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 11% a quarter earlier, followed by Financials and Technology.

Against the trend, Sabby Management opened a new position in Tompkins Financial worth $1.02M.

  • Sabby Management's largest Q3 2013 buy was Tompkins Financial: 288,454 shares worth $1.02M.
  • Sabby Management added most to Vertex Pharmaceuticals in Q3 2013, an estimated $25.6M increase.
  • Sabby Management's biggest Q3 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $28.4M.
  • Sabby Management fully exited AbbVie in Q3 2013, selling an estimated $14.7M.
  • Sabby Management's ten largest holdings make up 47% of its $1.54B portfolio in Q3 2013.
  • Sabby Management opened 90 new positions and closed 65 in Q3 2013.
  • Sabby Management's portfolio value rose 2.7% quarter-over-quarter to $1.54B.

Based on Sabby Management's 13F filing for Q3 2013, filed 14 Nov 2013.